Results 71 to 80 of about 9,672 (236)

Prediction of Hepatocellular Carcinoma After Direct‐Acting Antiviral Therapy Using Agile 3+ and End‐of‐Treatment Alpha‐Fetoprotein Levels in Patients With Hepatitis C

JGH Open, Volume 9, Issue 10, October 2025.
ABSTRACT Direct‐acting antivirals (DAAs) have dramatically improved sustained virological response (SVR) rates in patients with hepatitis C virus (HCV) infection. However, the risk of hepatocellular carcinoma (HCC) remains even after achieving SVR. We previously reported that alpha‐fetoprotein (AFP) levels at the end of treatment (EOT) were associated ...
Akifumi Kuwano, Masayoshi Yada, Kosuke Tanaka, Taikan Hamomoto, Kazuki Kurosaka, Hideo Suzuki, Kenta Motomura   +6 more
wiley   +1 more source

Curing Hepatitis C in Liver Transplant Recipients Is Associated with Changes in Immunosuppressant Use. [PDF]

, 2016
Background and aimsAll-oral interferon-free antivirals are highly effective in treating recurrent hepatitis C (HCV) infection in liver transplant (LT) recipients.
Bau, Sherona, Busuttil, Ronald W, Choi, Gina, Durazo, Francisco, El Kabany, Mohammed, Elashoff, David, Farid, Alexander, Grotts, Jonathan, Han, Steven, Jamal, Naadir, Jimenez, Melissa, Rheem, Justin, Saab, Sammy   +12 more
core   +2 more sources

Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study

Caspian Journal of Internal Medicine, 2020
Background: Treatment of hepatitis C virus (HCV) infection with recently introduced direct-acting antiviral agents (DAA) is effective and safe, however there is little known regarding safety and efficacy of generic DAAs in the real-life clinical setting.
Heidar Sharafi, Seyed Hoda Alavian, Bita Behnava, Mohammad Saeid Rezaee-Zavareh, Mehri Nikbin, Seyed Moayed Alavian   +5 more
doaj  

Direct Acting Antivirals for Treatment of Hepatitis C Infection in Patients with Advanced Liver Disease

The Korean Journal of Gastroenterology, 2016
Article: Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease (Gastroenterology 2015;149:649-659)
Woo Jin Chung
doaj   +1 more source

Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab

Liver International, Volume 45, Issue 10, October 2025.
ABSTRACT Background and Aims Hepatitis C virus (HCV) is a key driver of hepatocellular carcinoma (HCC). However, the impact of HCV eradication on systemic therapy remains unclear. We aimed to assess the safety and efficacy of direct‐acting antivirals (DAA) in patients treated with Atezolizumab plus Bevacizumab (AtezoBev).
Leonardo Stella, Giuseppe Cabibbo, Ciro Celsa, Roberta Ciccia, Alba Sparacino, Fabio Piscaglia, Francesco Tovoli, Andrea Arleo, Bernardo Stefanini, Massimo Iavarone, Roberta D'Ambrosio, Lucia Cerrito, Maria Pallozzi, Francesco Santopaolo, Fabio Marra, Claudia Campani, Chiara Mazzarelli, Raffaella Viganò, Raffaella Tortora, Alessio Aghemo, Stella De Nicola, Tiziana Pressiani, Lorenza Rimassa, Sherrie Bhoori, Salvatore Corallo, Laura Maiocchi, Andrea Martini, Caterina Soldà, Francesco Paolo Russo, Antonio Gasbarrini, Francesca Romana Ponziani   +30 more
wiley   +1 more source

HCV treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. [PDF]

, 2013
UNLABELLED: Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) cannot be achieved by harm reduction interventions such as needle exchange and opiate substitution therapy (OST) alone. Current HCV treatment is
Aitken, Allen, Berg, Burns, Cohen, Cohen, Cornish, Dahari, Dimova, Dore, Gane, Grebely, Grebely, Hagan, Hallinan, Harris, Health Protection Scotland and the University of the West of Scotland, Hellard, Hellard, Hickman, Innes, Iverson, Iverson, Jacobson, Kemp, Kim, Kimber, Kirwan, Lindenburg, Lindenburg, Liu, Liu, Ly, Maher, Martin, Martin, Martin, Mathers, McCaw, McInnes, Mehta, Micallef, Mondelli, Nelson, Nosyk, O'Keefe, Poordad, Poordad, Quinn, Shepard, Stoove, Sweeting, Turner, Vickerman, Vickerman, Wood, Zeiler   +56 more
core   +5 more sources

Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates [version 2; peer review: 3 approved]

F1000Research, 2020
We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CLpro) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and
Yu Wai Chen, Chin-Pang Bennu Yiu, Kwok-Yin Wong   +2 more
doaj   +1 more source

Update on hepatitis C virus resistance to direct-acting antiviral agents [PDF]

, 2014
Review[Abstract] Resistance to direct-acting antiviral (DAA) agents against hepatitis C virus (HCV) infection is driven by the selection of mutations at different positions in the NS3 protease, NS5B polymerase and NS5A proteins.
Cachay, Edward, Castro-Iglesias, Ángeles, Mena, Álvaro, Pedreira, José D., Poveda, Eva, Wyles, David L.   +5 more
core   +2 more sources

FIGO guideline on liver disease and pregnancy

International Journal of Gynecology &Obstetrics, Volume 170, Issue 1, Page 28-48, July 2025.
Abstract The number of women entering pregnancy with chronic liver disease is rising. Gestational liver disorders affect 3% of the pregnant population. Both can be associated with significant maternal and fetal morbidity and mortality. European guidance has recently been published to inform management.
Melanie Nana, Virna Medina, Cynthia Maxwell, Ciara McCormick, Gloria Taliani, Ulrich Beuers, Deborah Money, Bo Jacobsson, Anil Kapur, Titus Beyuo, Francisco Ruiloba, Graeme Smith, Lina Bergman, Sharleen O'Reilly, Patrick O'Brien, Mark Hanson, Mary Rosser, Claudio Sosa, Sumaiya Adam, Valerie Guinto, Liona Poon, Fionnuala McAuliffe, Catherine Williamson, on behalf of the FIGO Committee on Impact of Pregnancy on Long‐term Health, FIGO Committee on Infections during Pregnancy and the FIGO Division of Maternal and Newborn Health   +24 more
wiley   +1 more source

UPLC Method for Simultaneous Estimation of Ledipasvir and Sofosbuvir in Bulk and Dosage Forms and Their Stress Degradation Studies

, 2023
K Pushpa Kumari, D. Gowri Sankar
openalex   +2 more sources